Sujal Shah
2014
In 2014, Sujal Shah earned a total compensation of $725.2K as Chief Financial Officer at Cymabay Therapeutics, a 12% decrease compared to previous year.
Compensation breakdown
| Bonus | $150,000 |
|---|---|
| Option Awards | $234,391 |
| Salary | $330,000 |
| Other | $10,824 |
| Total | $725,215 |
Shah received $330K in salary, accounting for 46% of the total pay in 2014.
Shah also received $150K in bonus, $234.4K in option awards and $10.8K in other compensation.
Rankings
In 2014, Sujal Shah's compensation ranked 8,917th out of 13,032 executives tracked by ExecPay. In other words, Shah earned more than 31.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,917 out of 13,032 | 32nd |
Division Manufacturing | 3,330 out of 4,966 | 33rd |
Major group Chemicals And Allied Products | 1,128 out of 1,686 | 33rd |
Industry group Drugs | 900 out of 1,365 | 34th |
Industry Pharmaceutical Preparations | 689 out of 1,043 | 34th |
Source: SEC filing on April 21, 2016.
Shah's colleagues
We found two more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2014.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019